News
SIBN
11.61
-5.38%
-0.66
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
Reuters · 4h ago
SI-BONE Posts Double-Digit Q1 Growth, Raises 2026 Guidance; Stock Up
NASDAQ · 5h ago
SI-BONE INC <SIBN.O>: JEFFERIES CUTS TARGET PRICE TO $23 FROM $28
Reuters · 6h ago
Analysts Offer Insights on Healthcare Companies: SI-Bone (SIBN) and MoonLake Immunotherapeutics (MLTX)
TipRanks · 9h ago
Closing Bell Movers: Hims & Hers down 12% on earnings miss
TipRanks · 11h ago
SI-BONE raises 2026 revenue outlook to $230 million-$233 million
PUBT · 14h ago
SI-BONE GAAP EPS of -$0.10 beats by $0.09, revenue of $52.59M beats by $1.43M
Seeking Alpha · 14h ago
SI-Bone reports Q1 EPS (10c), consensus (19c)
TipRanks · 14h ago
SI-Bone raises FY26 revenue view $230M-$233M from $228.5M-$232.5M
TipRanks · 14h ago
SI-BONE beats Q1 revenue estimates; lifts 2026 guidance
Reuters · 15h ago
BRIEF-SI-BONE Q1 Revenue USD 52.588 Million Vs. IBES Estimate USD 51.1 Million
Reuters · 15h ago
*SI-BONE 1Q Loss/Shr 10c >SIBN
Dow Jones · 15h ago
*SI-BONE 1Q Loss $4.33M >SIBN
Dow Jones · 15h ago
*SI-BONE 1Q Rev $52.6M >SIBN
Dow Jones · 15h ago
Press Release: SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Dow Jones · 15h ago
Press Release: SI-BONE, Inc. Reports Financial -2-
Dow Jones · 15h ago
Earnings Scheduled For May 11, 2026
Benzinga · 1d ago
Weekly Report: what happened at SIBN last week (0504-0508)?
Weekly Report · 1d ago
SI-BONE: The Breakthrough Device Pipeline Meets Its First Real Deadline
Barchart · 1d ago
First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time SIBN stock news. You can receive the latest news about Si-Bone through multiple platforms. This information may help you make smarter investment decisions.
About SIBN
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.